<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2242">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131971</url>
  </required_header>
  <id_info>
    <org_study_id>213960</org_study_id>
    <nct_id>NCT05131971</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3888130B in Healthy Participants Aged 18-55 Inclusive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first time in human study designed to assess the safety, tolerability,&#xD;
      pharmacokinetics and PD of GSK3888130B over a range of dose levels in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to receive either GSK3888130B or placebo in single ascending dose cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This will be a double-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 110 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in laboratory parameters, vital signs and 12-lead electrocardiogram (ECG) findings</measure>
    <time_frame>Up to 85 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of GSK3888130B</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to time t (AUC[0 to t]) of GSK3888130B</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of GSK3888130B in serum</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of GSK3888130B</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of GSK3888130B</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of GSK3888130B</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive anti-drug antibodies against GSK3888130B</measure>
    <time_frame>Up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in derived free Interleukin-7 (IL-7) protein levels over time</measure>
    <time_frame>Baseline (Day 1) and up to 85 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD biomarker: T cell B-cell lymphoma 2 (Bcl-2) measured in blood over time</measure>
    <time_frame>Baseline (Day 1) and up to 85 days</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Participants receiving GSK3888130B at dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Participants receiving GSK3888130B at dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Participants receiving GSK3888130B at dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Participants receiving GSK3888130B at dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Participants receiving GSK3888130B at dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Participants receiving GSK3888130B at dose level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: Participants receiving GSK3888130B at dose level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3888130B</intervention_name>
    <description>GSK3888130B will be administered.</description>
    <arm_group_label>Cohort 1: Participants receiving GSK3888130B at dose level 1</arm_group_label>
    <arm_group_label>Cohort 2: Participants receiving GSK3888130B at dose level 2</arm_group_label>
    <arm_group_label>Cohort 3: Participants receiving GSK3888130B at dose level 3</arm_group_label>
    <arm_group_label>Cohort 4: Participants receiving GSK3888130B at dose level 4</arm_group_label>
    <arm_group_label>Cohort 5: Participants receiving GSK3888130B at dose level 5</arm_group_label>
    <arm_group_label>Cohort 6: Participants receiving GSK3888130B at dose level 6</arm_group_label>
    <arm_group_label>Cohort 7: Participants receiving GSK3888130B at dose level 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered.</description>
    <arm_group_label>Cohort 1: Participants receiving placebo</arm_group_label>
    <arm_group_label>Cohort 2: Participants receiving placebo</arm_group_label>
    <arm_group_label>Cohort 3: Participants receiving placebo</arm_group_label>
    <arm_group_label>Cohort 4: Participants receiving placebo</arm_group_label>
    <arm_group_label>Cohort 5: Participants receiving placebo</arm_group_label>
    <arm_group_label>Cohort 6: Participants receiving placebo</arm_group_label>
    <arm_group_label>Cohort 7: Participants receiving placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 55 years of age inclusive.&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, and cardiac monitoring.&#xD;
&#xD;
          -  Participants with a confirmed positive vaccination status for Severe Acute Respiratory&#xD;
             Syndrome Coronavirus 2 (SARS-CoV-2) vaccines administered at least 30 days prior to&#xD;
             dosing in the study.&#xD;
&#xD;
          -  SARS-CoV-2 screening test negative as per local guidance.&#xD;
&#xD;
          -  Participants with history of current/seasonal vaccination status for influenza or who&#xD;
             consent to receive influenza vaccine at least 30 days prior to dosing, if study dosing&#xD;
             is during influenza season (1st October to 30th April).&#xD;
&#xD;
          -  Body weight greater than or equal to (&gt;=) 50 kilograms (kg) and body mass index (BMI)&#xD;
             within the range 19.5-32 kilograms per square meter (kg/m^2) (inclusive).&#xD;
&#xD;
          -  Male and/or female of non-childbearing potential&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior medical history of anaphylaxis.&#xD;
&#xD;
          -  Immunodeficiency or autoimmunity assessed by medical history.&#xD;
&#xD;
          -  A history of recurrent infections.&#xD;
&#xD;
          -  Treatment of a chronic infection within 3 months prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Any acute infection (including upper respiratory tract infections and urinary tract&#xD;
             infections) which has not fully resolved within four weeks of dosing&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy.&#xD;
&#xD;
          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities.&#xD;
&#xD;
          -  Participants with a history of renal disease or renal abnormalities.&#xD;
&#xD;
          -  A clinically significant abnormality in the 12-lead ECG performed at screening.&#xD;
&#xD;
          -  A clinically significant abnormality in the Holter monitor performed at screening.&#xD;
&#xD;
          -  History of malignancy, including malignant or non-malignant skin cancer.&#xD;
&#xD;
          -  Participants with known SARS-CoV-2 positive contacts in the past 14 days.&#xD;
&#xD;
          -  Prior moderate/severe SARS-CoV-2 infection requiring oxygen supplementation or&#xD;
             admission to hospital.&#xD;
&#xD;
          -  Antibiotics or antiviral therapy within 30 days of dosing.&#xD;
&#xD;
          -  Receipt of live vaccination within 30 days of dosing or plan to receive live&#xD;
             vaccination during the study.&#xD;
&#xD;
          -  Use of prescription drugs or non-prescription drugs, including non-steroidal anti&#xD;
             inflammatory drug (NSAIDs), within 7 days prior to dosing, if in the opinion of the&#xD;
             Investigator (in consultation with the GlaxoSmithKline [GSK] Medical Monitor if&#xD;
             required) the medication will interfere with the study procedures or compromise&#xD;
             participant safety. The participant has participated in a clinical trial and has&#xD;
             received an investigational product within the following time period prior to the&#xD;
             first dosing day of the current study: 30 days, 5 half-lives or twice the duration of&#xD;
             the biological effect of the investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities within 12 months prior to dosing.&#xD;
&#xD;
          -  A positive drug/alcohol test at screening or Day -1&#xD;
&#xD;
          -  The participant is at high-risk of Mycobacterium tuberculosis (MTB) infection in the&#xD;
             opinion of the Investigator.&#xD;
&#xD;
          -  Current smoker or user of tobacco- or nicotine-containing products (e.g. nicotine&#xD;
             patches or vaporizing devices) during or within 30 days prior to study participation.&#xD;
&#xD;
          -  An average weekly intake of &gt;14 units of alcohol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Disala Fernando</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-Drug Antibodies</keyword>
  <keyword>Double-blind</keyword>
  <keyword>GSK3888130B</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Single Dose Escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

